Miami, FL (May 19, 2021) – Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, today announced that it has signed an exclusive distribution agreement with Apex Services Pakistan to import and distribute Zofin™ to hospitals and clinics in the country.
Under the agreement finalized this month, Apex Services will exclusively market, promote and distribute Zofin™ in the country of Pakistan in connection with treatments for COVID-19 patients, subject to the approval of all necessary licenses for the use of Zofin™ by the Drug Regulatory Authority of Pakistan. Earlier this month, the Drug Regulatory Authority of Pakistan approved the use of Zofin™ for a single patient on compassionate grounds.
If the use of Zofin™ is ultimately approved for use by a larger population, Apex Services will have exclusivity, subject to achievement of minimum sales levels. The initial term of the agreement is for one year and may be renewed based on certain conditions.
“With the execution of this distribution agreement, we are now better prepared to be able to provide additional help and further access to those in Pakistan who are suffering from complications from the COVID-19 virus pandemic to Zofin™. This will also support our plans to launch a broader clinical trial for Zofin™ in the country,” said Albert Mitrani, CEO of Organicell.
Zofin™ is an acellular biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs, without the addition or combination of any other substance or diluent. This product contains over 300 growth factors, cytokines, and chemokines as well as other extracellular vesicles/nanoparticles derived from perinatal tissues. Zofin™ is currently being tested in a phase I/II randomized, double blinded, placebo trial to evaluate the safety and potential efficacy of intravenous infusion of Zofin™ for the treatment of moderate to SARS related to COVID-19 infection vs placebo.
ABOUT ORGANICELL REGENERATIVE MEDICINE, INC.
Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR) is a clinical-stage biopharmaceutical company that harnesses the power of exosomes to develop innovative biological therapeutics for the treatment of degenerative diseases. The Company’s proprietary products are derived from perinatal sources and manufactured to retain the naturally occurring exosomes, hyaluronic acid, and proteins without the addition or combination of any other substance or diluent. Based in South Florida, the company was founded in 2008 by Albert Mitrani, Chief Executive Officer and Dr. Mari Mitrani, Chief Scientific Officer. To learn more, please visit https://organicell.com/.